清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Combination immunotherapy for hepatocellular carcinoma

肝细胞癌 医学 免疫疗法 肿瘤科 内科学 癌症研究 癌症
作者
Lorenza Rimassa,Richard S. Finn,Bruno Sangro
出处
期刊:Journal of Hepatology [Elsevier BV]
卷期号:79 (2): 506-515 被引量:181
标识
DOI:10.1016/j.jhep.2023.03.003
摘要

Single-agent immune checkpoint inhibitors (ICIs) have been tested in patients with advanced hepatocellular carcinoma (HCC), leading to objective response rates of 15-20%, mostly without a significant overall survival (OS) benefit. Furthermore, approximately 30% of HCC exhibits intrinsic resistance to ICIs. In the absence of predictive biomarkers to identify patients likely to benefit most from immunotherapy, research has moved to exploring combinations with potential activity in broader patient populations. Basket trials, including cohorts of patients with HCC, and early phase studies tested the combination of ICIs with anti-angiogenic agents as well as the combination of two different ICIs. The promising results that were achieved provided the rationale for the following phase III trials, which tested the combination of anti-PD-1/PD-L1 antibodies with bevacizumab, or tyrosine kinase inhibitors, or anti-CTLA-4 antibodies. Positive results from the IMbrave150 trial led to the practice-changing approval of atezolizumab-bevacizumab, the first regimen to demonstrate improved survival in the front-line setting since the approval of sorafenib. More recently, the HIMALAYA trial demonstrated the superiority of durvalumab-tremelimumab (STRIDE regimen) over sorafenib, establishing a new first-line option. In contrast, inconsistent results have been achieved with combinations of ICIs and tyrosine kinase inhibitors, with only one phase III trial showing an OS benefit. The rapid evolution of the therapeutic landscape for patients with advanced HCC has left many unanswered questions that will need to be addressed by future research. These include the choice and sequencing of treatments, identification of biomarkers, combinations with locoregional therapies, and development of new immunotherapy agents. This review summarises the scientific rationale and available clinical data for combination immunotherapy in advanced HCC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大模型应助科研通管家采纳,获得30
26秒前
科研通AI2S应助科研通管家采纳,获得10
26秒前
量子星尘发布了新的文献求助10
1分钟前
若水完成签到 ,获得积分10
1分钟前
1分钟前
喵喵完成签到 ,获得积分10
2分钟前
钱念波完成签到,获得积分10
2分钟前
量子星尘发布了新的文献求助10
2分钟前
3分钟前
Herbs完成签到 ,获得积分10
3分钟前
3分钟前
3分钟前
4分钟前
4分钟前
萝卜猪完成签到,获得积分10
4分钟前
宇文非笑完成签到 ,获得积分10
4分钟前
量子星尘发布了新的文献求助10
4分钟前
4分钟前
4分钟前
mikija完成签到,获得积分20
4分钟前
4分钟前
mikija发布了新的文献求助10
4分钟前
科目三应助我去打球采纳,获得30
5分钟前
5分钟前
我去打球完成签到,获得积分10
5分钟前
从容芮举报端庄的火龙果求助涉嫌违规
5分钟前
我去打球发布了新的文献求助30
5分钟前
5分钟前
5分钟前
微信研友发布了新的文献求助10
5分钟前
玛卡巴卡爱吃饭完成签到 ,获得积分10
5分钟前
量子星尘发布了新的文献求助10
5分钟前
5分钟前
慕青应助科研通管家采纳,获得10
6分钟前
共享精神应助科研通管家采纳,获得10
6分钟前
7分钟前
7分钟前
章鱼完成签到,获得积分10
7分钟前
传奇3应助Bo采纳,获得10
7分钟前
量子星尘发布了新的文献求助10
7分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976683
求助须知:如何正确求助?哪些是违规求助? 3520770
关于积分的说明 11204819
捐赠科研通 3257565
什么是DOI,文献DOI怎么找? 1798733
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806629